daraxonrasib

DRUG11 trials

Conditions

Advanced Solid TumorsAmpulla of Vater CarcinomaAmpullary CarcinomaBiliary Tract CancersCRCColorectal CancerColorectal Cancer (CRC)Extrahepatic Cholangiocarcinoma

Phase 1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

RecruitingNCT06128551

Revolution Medicines, Inc.Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

Start: 2023-11-14End: 2029-06-01Target: 534Updated: 2026-08-03

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

RecruitingNCT07349537

Revolution Medicines, Inc.Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma +7

Start: 2026-01-08End: 2028-10-01Target: 574Updated: 2026-07-10

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

RecruitingNCT07397338

Revolution Medicines, Inc.Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC) +3

Start: 2026-01-30End: 2029-05-01Target: 370Updated: 2026-08-03

First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

Not yet recruitingNCT07756281

Synnovation Therapeutics, Inc.Pancreatic Cancer, Pancreatic Acinar Carcinoma

Start: 2026-09-01End: 2029-06-01Target: 40Updated: 2026-08-10

Phase 2

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

RecruitingNCT07492680

Bristol-Myers SquibbSolid Tumors

Start: 2026-07-27End: 2032-05-20Target: 260Updated: 2026-08-25

Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

Not yet recruitingNCT07793253

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBiliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma +3

Start: 2026-11-01End: 2030-11-01Target: 55Updated: 2026-08-28

Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

RecruitingNCT06881784

Revolution Medicines, Inc.NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC +2

Start: 2025-05-06End: 2030-12-01Target: 590Updated: 2026-08-27

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

RecruitingNCT07252232

Revolution Medicines, Inc.Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma +2

Start: 2025-12-15End: 2030-07-10Target: 500Updated: 2026-08-25

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

RecruitingNCT07491445

Revolution Medicines, Inc.Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC +5

Start: 2026-03-09End: 2029-03-01Target: 900Updated: 2026-08-27

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

RecruitingNCT07805954

Revolution Medicines, Inc.Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC +5

Start: 2026-08-28End: 2030-04-01Target: 400Updated: 2026-09-08

Unknown Phase

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

NCT07573215

Revolution Medicines, Inc.PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma +5

Updated: 2026-09-01

Related Papers

Abstract CT215: RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC

Cancer Research2026-04-17

Abstract B046: Pan-RAS Inhibition as a novel therapeutic strategy for RAS-driven rhabdomyosarcoma

Cancer Research2026-03-05

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers

Journal of Medicinal Chemistry2025-03-0832 citations

Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers

Journal of Medicinal Chemistry2025-02-2422 citations